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Abstract
Interleukine-3 (IL-3) binds its receptor and initiates a cascade of signaling processes that regulate the proliferation and
differentiation of hematopoietic cells. To understand the detailed mechanisms of IL-3 induced receptor activation, we
generated a homology model of the IL-3:receptor complex based on the closely related crystal structure of the GM-
CSF:receptor complex. Model-predicted interactions between IL-3 and its receptor are in excellent agreement with
mutagenesis data, which validate the model and establish a detailed view of IL-3:receptor interaction. The homology
structure reveals an IL-3:IL-3 interaction interface in a higher-order complex modeled after the dodecamer of the GM-
CSF:receptor complex wherein an analogous GM-CSF:GM-CSF interface is also identified. This interface is mediated by a
proline-rich hydrophobic motif (PPLPLL) of the AA9 loop that is highly exposed in the structure of isolated IL-3. Various
experimental data suggest that this motif is required for IL-3 function through receptor-binding independent mechanisms.
These observations are consistent with structure-function studies of the GM-CSF:receptor complex showing that formation
of the higher-order cytokine:receptor complex is required for signaling. However, a key question not answered from
previous studies is how cytokine binding facilitates the assembly of the higher-order complex. Our studies here reveal a
potential cytokine–cytokine interaction that participates in the assembly of the dodecamer complex, thus linking cytokine
binding to receptor activation.
Citation: Dey R, Ji K, Liu Z, Chen L (2009) A Cytokine–Cytokine Interaction in the Assembly of Higher-Order Structure and Activation of the Interleukine-
3:Receptor Complex. PLoS ONE 4(4): e5188. doi:10.1371/journal.pone.0005188
Editor: Wenqing Xu, University of Washington, United States of America
Received February 19, 2009; Accepted March 14, 2009; Published April 7, 2009
Copyright:  2009 Dey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by research funding from National Institute of Heart, Lung and Blood to LC (HL076334) and the National Natural
Science Foundation of China to KJ and ZL (No. 30471505). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: linchen@usc.edu
Introduction
IL-3 and the closely related short-chain cytokine GM-CSF and
IL-5 are a subclass of the cytokines/growth factors secreted largely
by activated T cells [1]. These cytokines regulate the survival,
proliferation and differentiation of hematopoietic cells, while GM-
CSF has also been shown to regulate the function of dentritic cell
and T cells [2,3]. Dysfunction of this family of cytokines has been
implicated in a variety of pathologies including rheumatoid
arthritis and leukemia [4–8], whereas treatment with recombinant
cytokine of this family showed beneficial effect in a number of
clinical conditions [9–12], making them important targets of
therapeutic development.
IL-3, GM-CSF and IL-5 function by binding to their cognate
receptors expressed on the surface of cells in the hematopoietic
system. The receptors for IL-3, GM-CSF and IL-5 consist of a
cytokine-specific alpha subunit and a common beta subunit (bc)
that are both required for function [13–17]. The mechanism by
which cytokine binds and activates its receptor has been the
subject of extensive structural and functional studies [18]. As first
revealed in the human growth hormone receptor complex
structure [19], a general theme from these studies is that the
binding of cytokine induces dimerization of receptor subunits,
which brings signaling molecules (e.g. kinases) associated with the
cytoplasmic region of receptor subunits in close proximity for
trans-activation. However, higher-order cytokine:receptor com-
plexes have been implicated in receptor-mediated signaling [20],
and it becomes increasingly clear that each cytokine:receptor pair
has unique features in binding and activation mechanism.
Comparison of related cytokine:receptor complexes have been a
powerful way to explore the mechanisms of cytokine signaling
[20–23].
The binding of IL-3 to its receptor has been investigated
extensively using various approaches, including constructing
interspecies chimera [24,25], mapping the epitopes of neutralizing
antibodies [24,26], and mutagenesis [26–32]. These studies
provided rich biochemical and functional data on sites of IL-3
that are important for receptor binding and signaling activation. A
model of IL-3:receptor complex was also generated based on the
human growth hormone hGH:receptor complex structure [19,33].
While this model provided satisfactory interpretations for some of
the mutagenesis data, its accuracy is limited by the low homology
between the IL3:receptor complex and the hGH:receptor
complex. The crystal structure of a GM-CSF:receptor complex
has recently been determined [34]. IL-3 has a higher homology to
GM-CSF than hGH. Moreover, the receptors for IL-3 and GM-
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CSF:receptor complex offers a much better template for building a
more accurate model of the IL-3:receptor complex.
The mechanism by which IL-3, GM-CSF and IL-5 activate their
receptors has been a longstanding puzzle. Although the cytoplasmic
domain of the receptor alpha subunit is required for function, the
signaling kinase (JAK2) seems to bind only the beta subunit that
adopts an extended structure. Thus the classical model of cytokine-
induced dimerization of receptor subunits cannot explain signal
activation for this family of cytokines. Although it remains
controversial about which JAK kinases associate with the receptor
subunits and whether signaling is initiated by homo- or hetero
dimerization, the crystal structure of the GM-CSF:receptor complex
reveals a dodecameric assembly that provides a plausible mechanism
for receptor activation wherein the tyrosine kinase JAK2 associated
with the beta subunit are brought together for trans phosphorylation
[15–17]. Mutations on the receptor beta subunit designed to disrupt
the dodecamer assembly interface diminished the activity of the
receptor, providing functional evidence that the higher-order GM-
CSF:receptor complex is required for signaling [34].
The dodecameric assembly of cytokine:receptor complex has
also been proposed as part of the receptor activation mechanism
for IL-3 and IL-5 [34]. Indeed, beta subunits containing mutations
that presumably disrupt dodecamer assembly showed decreased
ability to mediate IL-3-dependent signaling [34]. However, an
intriguing question about this model of receptor activation is the
role of the cytokine itself. The protein interface in the GM-
CSF:receptor dodecamer shown to be functionally important by
mutagenesis is mediated entirely by the beta subunit. How the
cytokine itself controls the formation of the dodecamer complex
and signaling activation is not clear.
To address this question, we generated a homology model of the
IL-3:receptor complex based on the crystal structure of the GM-
CSF:receptor complex and took advantage of the vast amount of
biochemical data on the IL-3:receptor complex. The excellent
agreement between the model and previously published muta-
genesis data suggest that the homology structure represents a
reliable model for IL-3:receptor interaction. We identified a
cytokine-cytokine interaction interface in the modeled structure of
the IL-3:receptor complex and in the crystal structure of the GM-
CSF:receptor complex that participates in the assembly of the
dodecamer. In IL-3 this interface is mediated by a proline-rich and
exposed hydrophobic motif (PPLPLL) in the AA9 loop. Some
modifications of this motif by mutagenesis and by the binding of
neutralizing antibodies have been shown to affect the activity of
IL-3 without significantly changing its binding affinity for the
receptor [35]. These observations are in agreement with
mutagenesis studies of the GM-CSF:receptor dodecamer showing
that high affinity binding of cytokine to the receptor is not
sufficient for activation and that the formation of the higher-order
complex is an obligate step to initiate signaling. Our findings not
only provide further support for the dodecamer model of receptor
activation in the IL-3:receptor complex, but more importantly,
reveal a cytokine-cytokine interaction interface that participates in
the assembly of the dodecamer and hence signal initiation. The
structural model generated by this study will serve as a basis for
further studying the functional mechanisms of the IL-3:receptor
complex and for the development of therapeutics.
Materials and Methods
Selection of templates
The crystal structures of the GM-CSF:receptor complex (3.3 A ˚
resolution) [34] and the IL-4:IL-4R:IL-13RA ternary complex
(3.02 A ˚ resolution) [23]were used as templates to develop a
homology model of human IL-3 (hIL-3) bound to its receptor (the
hIL-3:receptor complex). The coordinates for both structures were
taken from the Brookhaven Protein Data Bank using the accession
numbers 3CXE and 3BPN, respectively. The NMR structure of a
functionally active hIL-3 variant SC-65369 (PDB accession
number 1JLI) was also taken from the Protein Data Bank to
build a structural model for the wild type hIL-3 (14–125). The
amino acid sequence of hIL-3 receptor a-chain was obtained from
ExPASy Proteomics Server (protein accession number P26951).
To select templates for modeling the IL-3 receptor a-chain, we
searched for its homologous sequences using BLAST (http://
www.ncbi.nlm.nih.gov/blast) against PDB database. It turns out
that the two domains of the IL-3 receptor a-chain align optimally
to two different protein sequences. The best template (with the
highest sequence homology) for domain 1 of IL-3 receptor a-chain
is chain C of 3BPN.pdb, whereas that for domain 2 is chain C of
3CXE.pdb.
Homology modeling
Homology models of hIL-3 receptor a-chain domain 1 (Pro103-
Ile207) and domain 2 (Leu208-Glu292) were developed based on
the crystal structure of IL-13 receptor a-chain (IL-13RA) and GM-
CSF receptor (GMR) a-chain domain 2 respectively, using the
program MODELLER [36]. The corresponding sequence
alignments are shown in Figure S1 and Figure S2. Domain 1 of
GMR a-chain is poorly defined in the crystal structure of the GM-
CSF:receptor complex[34]. To get the relative inter-domain
orientation, a combined model of hIL-3 receptor a-chain
(including both domain 1 and 2) was also developed based on
IL-13RA (sequence alignment is shown in Figure S3). Because
domain 1 and domain 2 of IL-3 receptor a-chain were modeled on
different templates, the linker region (residues Phe202 to Pro210)
was rebuilt with plausible backbone conformation and side chain
rotamers using program O [37]. The wild type hIL-3 model was
generated by in silico mutations from its mutant NMR structure
using the program O. A total of 14 substitutions were introduced
in the IL-3 NMR structure. The side chains of newly introduced
amino acid residues were manually adjusted to remove local
clashes and to allow potential hydrogen bonding and electrostatic
interactions. All the models were then put through energy
minimization in MODELLER with fixed backbones.
The hIL-3:receptor complex model
The structure of isolated GM-CSF is similar to its receptor
bound form [34,38]. We assume that the structure of hIL-3 bound
to its receptor is also similar to its free from. We therefore docked
IL-3 as a rigid body on the GM-CSF:receptor complex by
superimposing its structure with that of GM-CSF (Figure 1A). The
superposition is based on the backbone of the four conserved
helices (A–D) that shows an RMSD of 2.7 A ˚ for 50 C-a atoms
(Figure S4). The homology model of hIL-3 receptor a-chain is
docked onto the GM-CSF:receptor complex by superimposing its
domain 2 with that of GM-CSF receptor a-chains (Figure S5A).
Domain 1 of hIL-3 receptor a-chain, which is constructed based
on the template of IL-13RA domain1 (Figure S5), is fitted into the
ternary complex based on the inter-domain orientation of IL-
13RA with minor manual adjustments (see below). GM-CSF and
its receptor alpha chain were then removed from the combined
coordinates. With the remaining common b-chain, hIL-3 and the
receptor alpha chain were therefore placed together using the
molecular framework defined by the crystal structure of the GM-
CSF:receptor complex (Figure 1B). The complex model was
subject to energy minimization with fixed backbone using
IL-3:IL-3 Binding in Signaling
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removed manually in O by choosing different side chain rotamers.
Throughout the modeling process, only domain 1 and domain 4
from two different hIL-3 receptor b-subunits that are in contact
with IL-3 were included in the model refinement procedures. A
multiple sequence alignment among IL-3, GM-CSF, and IL-5 is
shown in Figure 1C with residues discussed in the text highlighted.
Overall, the homology model is based on the identical beta subunit
and closely related cytokine structures between IL-3 and GM-
CSF. Although the accuracy of the detailed hIL-3 receptor a-chain
structure may be limited by the modest sequence identity, the
overall arrangement of its two domains in the final complex can be
assigned with high confidence, so the role of the receptor a-chain
in the assembly of the dodecamer complex can be assessed with
reasonable certainty (see below).
Results
Overall structure of the IL-3:receptor complex
The canonical mode of cytokine/receptor interaction. IL-
3 is bound to the receptor through interfaces with the alpha subunit
(Interface I) and beta subunit (interface II). Upon binding to their
cytokine ligand, the alpha and beta subunit also interact with each
other through a binding interface termed interface III (Figure 1A
and 1B). The buried solvent accessible surface area between IL-3
and its receptor is 2267 A ˚ 2, which is comparable to that of the GM-
CSF:receptor complex. Domain 2 of IL-3Ra shows notable
difference from the corresponding domain of GMRa (Figure 1A).
Although most of the residues inside the beta sandwich core are
conserved (Figure S5A), the loop region (residues Gln241–Gln247)
involved in binding to the beta subunit and several other loops
(residues Arg229-Lys235 and residues Arg275-Phe281,here residues
are numbered according to hIL-3Ra) show significant divergence
from GMRa. These loops of IL-3Ra are substantially shorter than
theircounterpartsinGMRa(Figure1A,FigureS5A),theirstructure
and trajectory are highly constrained by the beta sandwich core.
Thus, the roles of these loops in binding with the beta subunit and
the cytokine can be assessed with reasonable certainty. Domain 1 of
IL-3Ra also likely has some differences from the corresponding
domain of GMRa. In the crystal structure of the GM-CSF:receptor
complex, domain 1 of GMRa is poorly defined, suggesting its
relatively high flexibility in the complex. In the homology model of
the IL-3:receptor complex, the placement of hIL-3Ra domain 1 is
guided by the inter domain orientation of IL-13Ra The final
Figure 1. Modeling of the IL-3:receptor complex. (A) The structure of IL-3 (red) is superimposed on that of GM-CSF (yellow). The IL-3 receptor
alpha chain domain 2 (a2, blue) is superimposed on the corresponding domain of GM-CSF receptor alpha chain (light magenta). The position of IL-3
receptor alpha chain domain 1 (a1, blue) is fitted as described in text. Domain 1 of one beta subunit (b1) and domain 4 of the other (b49) are shown in
green. The rest of the beta dimer is not shown. The three interfaces of the complex discussed in the text are labeled. The color scheme is used
throughout the illustration unless otherwise indicated; (B) The resulting model of the IL-3:receptor complex after removing GM-CSF and its receptor
alpha subunit, shown in ribbon covered with transparent surface; (c)sequence alignment of IL-3, GM-CSF and IL-5. Helices in IL-3 are indicated by
horizontal bar in red. Residues discussed in the text are highlighted in different colors: green shade, residues interacting with the receptor b-subunit
in IL-3 and GM-CSF; blue shade, residues of IL-3 that interact with the receptor a-subunit; magenta shade, residues of GM-CSF that interact with the
receptor a-subunit; red font, functionally important residues from mutagenesis studies. Boxed residues are involved interface V interaction. Residue
numbering above the sequence is for IL-3.
doi:10.1371/journal.pone.0005188.g001
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to account for potential IL-3:IL-3Ra interactions defined by
mutagenesis studies (see below).
Higher-order structure of the IL-3:receptor complex. We
applied symmetry operations derived from the GM-CSF:receptor
crystal to generate both hexamer and dodecamer of the hIL-
3:receptor complex (Figure 2A and 2B). The resulting higher-order
complex shows that the components of the dodecamer fit nicely with
each other. A unique feature of the receptors for GM-CSF, IL-3 and
IL-5isthatthebetasubunitformsanintertwineddimer[39].Invitro
binding studies suggest that domain 1 and domain 4 from different
beta subunits act together to bind the cytokine ligand [40,41]. The
crystal structure ofthe GM-CSF:receptor complex revealsthat this is
indeed the case. Domain 1 of one beta subunit and domain 4 of the
other forma composite surfaceto bind GM-CSFat interfaceII, such
that two cytokines and two GMRa chains are cross linked by the
beta dimer so as to form a 2:2:2 hexamer (Figure 1 in Hansen et
al.[34]). In the crystal of the GM-CSF:receptor complex, two
hexamers pack head-to-head together to form a dodecamer wherein
domain 4 of two adjacent beta subunits contact each other through
an extensive protein interface (Figure 3 in Hansen et al. [34]). This
interface, referred to as interface IV, has been shown by mutagenesis
and neutralizing antibodies to be important for receptor activation.
The same interface is also present in the modeled IL-3:receptor
complex (Figure 3A). As discussed below, we identified another
protein-protein interaction interface involved in the assembly of the
GM-CSF:receptor dodecamer (Figure 3B). This interface, termed
interface V,ismediatedbythe loop regionbetweenhelixA andhelix
B of GM-CSF bound to two different hexamers. This region of GM-
CSF contains a short alpha helix that forms the major part of the
interface. In the modeled hIL-3:receptor complex, the cor-
responding region of IL-3, the AA9 loop, is similarly positioned to
forman analogous interaction interfaceinthe dodecamer(Figure 3A
and 3C).
Comparing the IL-3:receptor structure model with
biochemical data
In the following sections, we will analyze the modeled structure
in the context of biochemical data to gain insights into the
molecular details of IL-3:receptor interactions. We also seek to
Figure 2. Higher-order structure of the IL-3:receptor complex. (A) Assembly of one trimeric IL-3 (red), IL-3Ra (blue), and IL-3Rb (green)
cytokine/receptor complex with the other (pink, marine and forest) into the hexamer. The dodecameric partners at each end are shown in magenta
(IL-3), orange (IL-3Rb) and cyan (IL-3Ra, domain 1 is omitted in this view), with the interaction interface indicated by a dashed box. (B) Side view of the
complex showing the arched structure. Only the foreground structure is shown in this view.
doi:10.1371/journal.pone.0005188.g002
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structure-function analysis of the higher-order IL-3:receptor
complex.
Protein interfaces involved in IL-3 binding
IL-3 binds the IL-3R alpha subunit with modest affinity through
interface I but not to the beta subunit alone. Upon IL-3 binding to
the alpha subunit, the beta subunit dimer is recruited to the
complex through interfaces II and III (Figure 1A and 1B). These
interfaces act cooperatively to stabilize the overall complex,
resulting in high affinity binding of the cytokine ligand. We will
discuss interface II first because it is constructed with minimal
model manipulation. This interface is defined by the common beta
subunit and by the experimentally derived IL-3 structure
superimposed on GM-CSF as a rigid body. At interfaces I and
III, on the other hand, loops of IL-3R alpha subunits required
local adjustments to dock onto IL-3 and the beta subunit.
At interface II (Figure 4), helix A and C of IL-3 bind a
composite protein surface formed by the AB and EF loops of
domain 1 of one beta subunit and the BC and FG loops of domain
4 of the other. A prominent feature of interface II is the intimate
interaction between Glu22 (residues in IL-3 are italicized
throughout the text) of IL-3 and a group of aromatic residues of
the beta subunit, including Tyr39, Tyr365, His367 and Tyr421
(Figure 4A). In addition to extensive van der Waals contacts, the
carboxylate group of Glu22 is in position to form a hydrogen bond
with the phenolic hydroxyl group of Tyr421. An adjacent patch of
interactions involves Met19, Ser76, Ile77 and Ala73 of IL-3 that
pack against Ser102, Val104, Val105 and Thr106 on the beta
subunit. Asn15, Asn18, Thr25, and His26 of IL-3 are also in close
proximity to contact the beta subunit (Figure 4B). The detailed
interactions at interface II are similar to those seen in the GM-
CSF:receptor complex but also show some differences. For
example, a salt bridge between Lys72 of GM-CSF and Asp107
of the beta subunit is missing at interface II of the IL-3:receptor
complex, whereas Ile77 of IL-3 may bind the hydrophobic pocket
formed by Ser102, Val104, Val105 and Thr106 of the beta
subunit better than the proline counterpart (Pro76) in GM-CSF.
The structural features of interface II are consistent with
mutagenesis data on the functional roles of interface residues
Figure 3. A cytokine–cytokine interaction interface in the dodecamer. (A) A ribbon/surface presentation of interface IV and V (dashed boxes)
in the modeled IL-3:receptor complex. Only domain 4 of the interaction beta subunit and IL-3 are shown in this view. The two residues at interface IV
(Glu359 and Lys362) that engage in potential charge repulsion are indicated. The arrows indicate the two fold symmetry axis that runs through both
interface IV and V. (B) A top view of interface V in the crystal structure of the GM-CSF:receptor complex (dashed box) and its relative position with
respect to other components of the complex. The receptor alpha subunit domain 1 showed only partial density of a few beta strands that are
represented by backbone trace here. (C) A top view of interface V (dashed box) mediated by the AA9 loop in the modeled IL-3:receptor complex.
doi:10.1371/journal.pone.0005188.g003
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center of the interface is highly sensitive to mutations of Glu22 of
IL-3 and Tyr421 of the beta subunit [30,31,33,42,43]. Even subtle
changes, such as substituting Tyr421 with phenylalanine in the
beta subunit, abolish the high affinity binding of IL-3 and GM-
CSF to the receptor.
At interface I, helix A, A9 and D of IL-3 bind domain 1 and
domain 2 of IL-3R alpha through two distinct patches of protein-
protein interactions, one dominated by electrostatic interactions
while the other rich in hydrophobic/van der Waals contacts. The
charge interaction patch is formed between helix A of IL-3 and
domain 2 of IL-3R alpha, where Asp21 and Glu119 of IL-3 are in
position to engage in electrostatic interaction with Arg277 and
Arg234 of IL-3R alpha, respectively (Figure 5A). Arg234 of IL-3R
alpha is also in position to interact with Ser17 of IL-3 through
hydrogen bonding. For the hydrophobic patch, residues located on
various loops of IL-3R alpha domain 1, including Val200, Phe202,
Ser177–Ser179, and Ala143-Arg146, project toward the cytokine
to interact with Gln124, Asn120, Thr117, Lys116, Phe113, Gly42,
Gln45, Asp46, and Met49 on helix D and A9 of IL-3. Most notably,
Phe202 of IL-3R alpha is poised to insert into a hydrophobic
pocket formed by Phe113, Thr112 and the aliphatic side chain of
Lys116 on IL-3 (Figure 5B). Consistent with the structure model, a
number of IL-3 residues located at interface I, including Ser17,
Asn18, Asp21, Arg108, Phe113, Lys116 and Glu119 have been shown
to be important for receptor binding and activation by
mutagenesis [29,30,32] (Figure 1C). The loss of function for
mutations Ser17Lys, Asn18Lys, Thr25Arg and Glu119Arg of IL-3
could be explained by charge repulsion with Arg234 and Arg277
of IL-3R alpha [32], while that for Phe113A could be explained by
diminished hydrophobic interactions with Phe202 of IL-3R alpha.
Interestingly, a number of IL-3 mutations, such as Lys116Val,
Gln45Val, Lys116Trp, and Thr112Arg, showed enhancement in
receptor binding and/or cellular activities [29,31,32]. Remark-
ably, these residues are located around Phe113 in the folded
structure of IL-3. Substitution of these hydrophilic residues with
hydrophobic residues or residues with longer aliphatic side chain
could therefore augment the hydrophobic interaction at interface I
and hence enhance the activity of mutated IL-3.
At interface III, the loop region of Arg257-Gln261 in IL-3R
alpha, which forms a major part of the binding site of beta domain
4, is very similar to the corresponding region of GMR alpha in
sequence, structure and interaction with beta-subunit (Figure 5C).
On the other side of the beta sandwich (Figure 5C), residues
Lys244, Arg245 and Gln247 of IL-3R alpha are also involved in
beta subunit binding. This part of interface III in the IL-3:receptor
complex is different from that of the GM-CSF:receptor complex
because the loop region following the b-strand Lys235-Leu240 is
much shorter in IL-3Ra than in GMRa (Figure S5A). Overall,
interface III in the IL-3:receptor and GM-CSF:receptor complex-
es show significant similarity as well as some differences.
Protein–protein interactions involved in the assembly of
the dodecamer
A dodecamer complex is formed in the crystal of the GM-
CSF:receptor complex [34]. Interactions between domain 4 of two
adjacent beta subunits belonging to two different hexamers
constitute a significant part of the protein interface (interface IV)
in the assembly of the dodecamer. Residues on several beta strands
of domain 4, including Gln346 - Asp352, Arg357, Glu359, Lys362
and Arg432-Asp435, are in position to contact each other at this
interface [34]. These interactions are also conserved in the IL-
3:receptor dodecamer complex (Figure 3A), which may also be
involved in receptor activation. Consistent with this hypothesis,
extensive mutations at interface IV not only reduced the activity of
the GM-CSF:receptor complex but also that of the IL-3:receptor
complex [34].
In the crystal structure of the GM-CSF:receptor complex,
Asn261 of the a subunit domain 2 of one hexamer makes a small
contact to Glu430 and Arg 432 of the beta subunit domain 4 of the
other hexamer (Figure S6). The contribution of this interaction to
the dodecamer assembly is likely small due to the limited contact.
Moreover, it is absent in the modeled hIL-3:receptor dodecamer
complex because IL-3R alpha has a much shorter loop in this
region than GMR alpha (Figure S5A). These observations raise
the question on how cytokine controls the assembly of the
dodecamer.
Further examination of the GM-CSF:receptor crystal reveals
that another protein-protein interaction interface, mediated by the
Figure 4. Protein–protein interactions at interface II. (A) A zoom-
out view of the interface showing the secondary structural elements of
IL-3 and the receptor involved in the reaction. The interaction between
Glu22 of IL-3 and a number of aromatic residues from the receptor beta
subunit (Tyr39, Tyr365, His367, Tyr421) is shown. (B) A zoom-in view
showing additional details of interface II, including the interactions
between Met19, Ile77 and Ala73 of IL-3 and Ser102, Val104, Val105 and
Thr106 on the receptor beta subunit.
doi:10.1371/journal.pone.0005188.g004
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(Figure 3B, Figure 6A and 6B). This interface, termed interface V,
is located directly above interface IV and shares the same twofold
symmetry axis with interface IV (Figure 3A). These structural
features suggest that interface V and IV may form concertedly and
act cooperatively in the assembly of the dodecamer. Interface V in
the GM-CSF:receptor complex buries about 646 A ˚ 2 solvent
accessible surface area that includes residues Leu28-Asn37 and
Glu104 from two interacting GM-CSF molecules. The interface is
mediated by two short helices and has a hydrophobic core
consisting of Ala33, Met36, Ala339 and Met369 (the prime sign
denotes residues from symmetry partner), which is surrounded by
extensive van der Waals contacts and hydrogen bond interactions
(Figure 6A). For example, Arg30 forms a hydrogen bond with the
main chain carbonyl of Leu289, Thr32 forms a hydrogen bond with
Glu1049, while Asn37 form a bidendate hydrogen bond with Asn379
(Figure 6B). These structural features suggest that interface V has
excellent shape and chemical complementarity and likely makes
significant contribution to the dodecamer assembly. It is
interesting to note that interface V in GM-CSF is bounded by
two glycosylation sites, Asn27 and Asn37, suggesting that the sugar
chain attached at the periphery of interface V could augment the
protein-protein interaction and hence the dodecamer stability
[44,45].
In the modeled IL-3:receptor complex, a similar interface is
formed between the AA9 loop of IL-3 bound to two opposing
hexamers (Figure 3A and 3C). Both IL-3 and GM-CSF have an
extended loop between helix A and B but share little sequence
conservation in this region (Figure 1C), suggesting that interface V
can form in the two family members but not between them. The
AA9 loop of IL-3 contains a characteristic PPLPLL motif (residues
30–35 in human IL-3). The exposed and hydrophobic nature of
this motif suggests that the AA9 loop has a high tendency to bind
other hydrophobic protein surface. Here in the IL-3:receptor
Figure 5. Protein–protein interactions at interfaces I and III. (A) A charged interaction patch between helix A of IL-3 and domain 2 of IL-3R
alpha. Here Asp21 and Glu119 of IL-3 engage in electrostatic interaction with Arg277 and Arg234 of IL-3R alpha, respectively. (B) A hydrophobic
interaction patch between IL-3 and IL-3R alpha domain 1. Note that Phe202 of IL-3R alpha inserts into a hydrophobic pocket formed by Phe113,
Thr112 and the aliphatic side chain of Lys116 on IL-3. (C) Foreground: the loop region between Arg257 and Gln261 of IL-3R alpha (blue) is very similar
to the corresponding region of GMR alpha (magenta) in sequence, structure and interaction with beta-subunit (green). Background: residues Lys244,
Arg245 and Gln247 of IL-3R alpha also contact the beta subunit.
doi:10.1371/journal.pone.0005188.g005
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molecules are poised to interact with each other (Figure 6C and
6D). Although the detailed interactions at interface V of IL-3 await
direct experimental determination, our modeling suggest that
Leu32, Leu34 and Leu35 are in positions to interact with their
counterparts in the symmetric partner, much like the leucine
zipper interaction observed in many protein complexes. However,
unlike classical leucine zippers where leucine residues are
presented by alpha helix, the conformation of the AA9 loop of
IL-3 seems to be partially restricted by a series of proline residues,
which may be required to reduce non-specific hydrophobic
interactions.
Though far away from the receptor binding sites, the PPLPLL
motif (Pro30-Leu35) has been shown to be a functionally important
site on IL-3 by a number of experiments. In mapping functional
sites of IL-3 using monoclonal antibodies that bind IL-3 and
inhibit its activity, Lokker et al. showed that the epitopes of two
neutralizing antibodies were located between Leu32 and Asp36
[26,35]. Deletion of a significant portion of this region, such as
Pro30-Leu33 (del-Pro30-Leu33) and Pro30-Leu34 (del-Pro30-Leu34),
diminished the activity of IL-3. Site-specific mutations of residues
in this region affected the activity of IL-3 both positively and
negatively. While the Leu34Glu mutation showed little effect on the
function of IL-3, the Leu34Gly mutant showed much reduced
activity than the wild type IL-3. On the other hand, substitution of
Pro33 with Asn (Pro33Asn) and Gly (Pro33Gly) enhanced the specific
activity of IL-3. Gain-of-function mutations of IL-3 have also been
identified in the PPLPLL motif in a saturation mutagenesis study
[31], where Leu32Arg, Leu34Ser and Leu34Met showed increased
activity. Many of the loss-of-function mutations such as del-Pro30-
Leu33, del-Pro30-Leu34, and Leu34Gly also showed decreased
affinity for the receptor [35]. How these modifications affect the
binding of IL-3 to its receptor is not clear since the AA9 loop does
not make direct contact to either subunits of the receptor in the
modeled structure (Figure 3A and 3C). While these negative results
seem to contradict the model of interface V mediated signal
activation through dodecamer assembly, it must be kept in mind
that loss-of-function of mutations often involve complex but trivial
mechanisms, such as protein mis-folding or aggregation, especially
considering the hydrophobic nature of the AA9 loop (see discussion
Figure 6. Detailed protein–protein interactions at interfaces V. (A) Detailed GM-CSF:GM-CSF interactions in the crystal structure of the GM-
CSF:receptor dodecamer (top view); (B) side view of (A); (C) Detailed IL-3:IL-3 interactions in the modeled structure of the IL-3:receptor dodecamer
(top view); (D) side view of (C).
doi:10.1371/journal.pone.0005188.g006
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much more mechanistically revealing. Here these mutations
enhanced the specific activity of IL-3 substantially with little to
modest effect on the binding affinity for the receptor. Most
notably, the Pro33Gly mutant showed 14-fold increase in activity
but virtually the same receptor affinity as compared with the wild
type protein in cell-based assays, indicating that modifications in
the PPLPLL motif of the AA9 loop can affect the function of IL-3
through mechanisms independent of receptor binding. Animal
studies of an IL-3 triple mutant (Pro33Gly/Trp104Glu/Asn105Asp)
also showed that modifications of the PPLPLL motif and its
nearby regions could enhance the specific activity of IL-3
significantly under physiological conditions (Kunmei Ji and
Zhigang Liu, data not shown). Mutations on interface IV have
also been shown to disrupt the function of the receptor without
affecting the binding of the cytokine [34]. These observations
suggest that interface V identified here contribute to the activation
of the receptor through a similar mechanism to interface IV,
namely the assembly of the dodecameric cytokine:receptor
complex (Figure 7).
Discussion
The homology model of the IL-3:receptor complex generated in
this study provides a molecular framework to analyze a large body
of mutagenesis data on the roles of specific residues in IL-
3:receptor complex formation and function. These analyses reveal
three prominent features at the IL-3:receptor interface (Figures 1,
4, and 5). First is the tight interaction between Glu22 of IL-3 and a
group of aromatic residues on the receptor beta subunit. This
patch of interaction is highly sensitive to mutations, suggesting its
critical role in the binding of IL-3 to the receptor [30,31,33,42,43].
The second feature is a perfectly matched charge interface
between Asp21 and Glu119 of IL-3 and Arg277 and Arg234 of IL-
3R alpha. This feature is consistent with a series of mutational
studies showing that Ser17Lys, Asn18Lys, Thr25Arg and Glu119Arg
can severely disrupt the function of IL-3, presumably by
introducing charge repulsion with Arg277 and Arg234 of IL-3R
alpha [29,30,32]. The third feature is a hydrophobic interface
formed between Phe202 of IL-3R alpha and a hydrophobic pocket
lined by Phe113, Thr112 and the aliphatic side chain of Lys116 on
IL-3. This feature provides potential interpretations for the loss-of-
function mutation of Phe113Ala as well as the gain of function
mutations of Lys116Val, Gln45Val, Lys116Trp, and Thr112Arg,
which may decrease or increase the hydrophobic interaction,
respectively [29,31,32].
A large number of IL-3 residues, including some at the IL-
3:receptor interface, show high tolerance to mutations [31,33].
This fact does not necessarily indicate poor quality of the structure
of the IL-3:receptor complex generated by homology modeling. It
is very common that interactions observed in experimentally
derived structures may or may not have energetic contribution to
binding and function. As shown in this study, structure-based
analysis of specific mutations that alter the binding and function
with defined chemical changes is needed to understand the
functional mechanism of protein-protein interactions between IL-3
and its receptor. Overall, the homology model of the IL-3:receptor
complex is in excellent agreement with previously published
mutagenesis data, thus providing a reliable framework for
analyzing the IL-3:receptor interaction.
The beta subunit of IL-3, GM-CSF, and IL-5 receptors forms a
stable dimer [34,39], where a cytokine-binding site is located at
each end of the extended dimer structure. Such an unusual
structural feature leads to the assembly of the cytokine:receptor
hexamer when two cytokine:receptor alpha subunit complexes are
recruited to the beta dimer (Figures 2 and 7). Although the
cytoplasmic domain of the receptor alpha chain is required for
function [13,14], it does not appear to be associated with any
signaling kinases [15–17,34]. The cytoplasmic region C-terminal
to domain 4 of the beta subunit, on the other hand, has been
shown to bind JAK2 that is capable of initiating the signaling
cascade [34]. However, the membrane proximal domain (domain
4) of the beta subunit in the 2:2:2: hexamer is 120 A ˚ apart, raising
the question on how trans-phosporyaltion of JAK2 and signal
activation are achieved in the cytokine:receptor complex.
The crystalstructure of the GM-CSF:receptor complex providesa
potential answer to this question. In the crystal lattice, two GM-
CSF:receptor hexamers stack against each other to form a
dodecamer, which brings domain 4 of two beta subunits from
different hexamers in close proximity. Initial support for this model
of dodecamer-dependent activation came from mutagenesis analysis
of a protein interface (interface IV) between domain 4 of two
adjacent beta subunits (Figure 3A). However, a puzzling aspect of
this model is how the assembly of the dodecamer, which is
apparently required for receptor activation, is coupled to cytokine
binding to the receptor, which must be the initiation event of
signaling. Interface IV is mediated entirely by the beta subunit,
suggesting that it could form stochastically and transiently without
the binding ofcytokine.Inthisregard itisinteresting tonotethat low
level phosphorylation of JAK2 does occur in the absence of cytokine
(see Figure 4C in Hansen et al. [34]) (Figure 7). The protein-protein
interactions at interface IV are largely polar without significant
chemical complementarity in hydrogen bonding and electrostatic
interaction. In fact, a number of charged residues such as Glu359
and Lys362 seem to engage in electrostatic repulsion (Figure 3A),
which may play a role in reducing background signaling. These
structural features suggest that interface IV will not form stably in
solutionbyitself.However,itsstructuralintegrityisstillimportantfor
function as extensive but not limited mutations at this interface
diminished the activity of the receptor. In the event of cytokine-
mediated signaling, interface IV will most likely work with other
protein interaction interfaces that provide the driving force for the
dodecamer assembly and signaling activation.
One such interface is a cytokine-cytokine interaction identified in
this study, which we termed interface V. In the crystal structure of
the GM-CSF:receptor complex, the AB loop of GM-CSF bound to
adjacent hexamers contact each other through a significant binding
interface (Figure3B,Figure6Aand 6B).Although no functional data
is currently available for the AB loop of GM-CSF, this interface
could contribute tothe dodecamer assemblyand receptor activation.
In the modeled IL-3:receptor complex, the AA9 loop of two adjacent
IL-3 molecules are similarly positioned to form an interaction
interface through the PPLPLL motif (Figure 3C, Figure 6C and 6D).
Here a large body of data is available to assess the functional roles of
thismotifinIL-3.WhiletheimportanceofthePPLPLLmotifinIL-3
has long been demonstrated by neutralizing antibodies and by
mutagenesis [26,35], the observation that a number of mutations in
this region can increase the specific activity of IL-3 without changing
the binding affinity of the receptor has been puzzling [35]. In the
dodecameroftheGM-CSF:receptorcomplex,mutationsatinterface
IV have also been shown to disrupt the function of the receptor
without changing the binding of IL-3 and GM-CSF [34]. These
observations suggest that interface V, which is mediated entirely by
cytokine-cytokine interactions, could contribute to the receptor
activation through the assembly of the dodecamer (Figure 7).
The AA9 loop of IL-3 is conserved between human,
chimapanzee and gibbon but shows variations across a range of
other species including rhesus, tamarin, marmoset, sheep, bovin,
IL-3:IL-3 Binding in Signaling
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mutations [31], suggesting that sequence conservation in this
region is not absolutely required for maintaining interface V
interactions. Because the AA9 loop makes few contacts to the main
body of the IL-3 structure, it is highly exposed and flexible.
Interactions between the AA9 loop from two adjacent IL-3
molecules most likely involve co-folding. Such a mechanism of
interaction will make interface V more tolerant to mutations than
protein-protein interaction mediated by rigid structures, as long as
the mutations, which will occur simultaneously on both sides of the
interface, permit the co-folding of the modified AA9 loop. This
mechanism of interaction may also explain why a large number of
Figure 7. Activation mechanism of the IL-3:receptor complex. (A) In the absence of cytokine, the receptor subunits are scattered on the cell
surface, where the beta dimer, which binds JAK2 through its cytoplasmic region, form transient tetramer through interface IV that may contribute to
residual phosphoryaltion of JAK2. (B) In the presence of IL-3, the cytokine and receptor subunits assembly into a dodecamer that is stabilized by IL-
3:IL-3 interaction, leading to robust signal activation through JAK2 trans-phosphorylation. (C) A variety of experimental data showed that
modifications of the AA9 loop of IL-3, including deletion, loss-of-function mutations, and antibody binding, diminished the activity IL-3, whereas gain-
of-function mutations are also frequently observed in this region that enhanced the IL-3 without affecting the receptor binding affinity.
doi:10.1371/journal.pone.0005188.g007
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AA9 loop (Figure 1C and Figure 7C). In the context of natural
cytokine:receptor complex, sequence divergence and the co-
folding mechanism at interface V would provide a way to confer
specie-specific activity of IL-3 or member-specific function in the
IL-3, GM-CSF, IL-5 family. In this regard, it is interesting to note
that IL-5 forms a stable dimer [46]. Although the IL-5 dimer
interface is incompatible with interface IV observed in the GM-
CSF:receptor dodecamer [34], it may represent a cytokine-
cytokine interaction that has evolved into a stable form for
function, probably through the assembly of a different type of
higher-order cytokine:receptor complex.
In summary, our analysis of the IL-3:receptor complex by
homology modeling and published mutagenesis data provides
further evidence for the dodecamer-model of receptor activation
proposed for GM-CSF and IL-3 [34]. Our studies suggest that the
AA9 loop in IL-3 and the analogous region in GM-CSF participate
in the assembly of the dodecamer. Such a revised model of
dodecamer-dependent activation solves the paradox in the
previous model and provides a mechanism by which cytokines
control the activation of receptor-mediated signaling (Figure 7).
Supporting Information
Figure S1 Sequence alignment between domain 1 of IL-3
receptor alpha chain (IL3R-a1) and the corresponding region in
IL-13 (IL13R-a). The arrows above the sequence denote regions
of beta strand. Identity and similarity are indicated by standard
conventions below the sequence. These conventions are used
throughout the illustration. The sequence between residue 176
and 177 in IL-3 corresponds a large loop insertion in IL-13R
alpha chain (residues192–199).
Found at: doi:10.1371/journal.pone.0005188.s001 (1.56 MB TIF)
Figure S2 Sequence alignment between domain 2 of IL-3
receptor alpha chain (IL3R-a2) and the corresponding region in
GM-CSF receptor alpha chain (GMR-a2).
Found at: doi:10.1371/journal.pone.0005188.s002 (1.56 MB TIF)
Figure S3 Sequence alignment between the full length IL-3
receptor alpha chain (IL3R-a) and IL-13 receptor alpha chain
(IL13R-a).
Found at: doi:10.1371/journal.pone.0005188.s003 (1.56 MB
DOC)
Figure S4 The structure of IL-3 (red) is superimposed on that of
GM-CSF (yellow) as a rigid body. Representative residues
involved in the core packing of the helix bundle are shown to
demonstrate the similar folding interactions between the two
proteins. The residues are colored according to their host proteins.
Only residues of IL-3 are labeled. The AA9 loop of IL-3 and the
AB loop of GM-CSF are indicated.
Found at: doi:10.1371/journal.pone.0005188.s004 (1.56 MB
DOC)
Figure S5 (A) Superposition of domain 2 of IL-3 receptor alpha
chain (IL-3R-a2, blue) with the corresponding domain of GM-
CSF receptor alpha chain (GMR-a2, magenta). Representative
residues involved in the packing of the beta sandwich core are
shown to demonstrate the similar folding interactions between the
two proteins. The residues are colored according to their host
proteins. Only residues of IL-3 are labeled. The two long loops in
GMR-a2 located at the end of the beta barrel correspond to much
shorter loops in IL-3. (B) Superposition of domain 1 of IL-3
receptor alpha chain (IL-3R-a1, blue) with the corresponding
domain of IL13 receptor alpha chain (IL13Ra, pink). Represen-
tative residues involved in the packing of the beta sandwich core
are shown to demonstrate the similar folding interactions between
the two proteins. The residues are colored according to their host
proteins. Only residues of IL-3 are labeled.
Found at: doi:10.1371/journal.pone.0005188.s005 (1.55 MB TIF)
Figure S6 In the crystal structure of the GM-CSF:receptor
complex, Asn261 of the a subunit domain 2 of one hexamer makes
a small contact to Glu430 and Arg 432 of the beta subunit domain
4 of the other hexamer.
Found at: doi:10.1371/journal.pone.0005188.s006 (1.56 MB
DOC)
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